Scarica l'app Stockscreener
0.96
3.73%
-0.0372
Precedente Chiudi:
$0.9972
Aprire:
$0.99
Volume 24 ore:
11,450
Relative Volume:
0.17
Capitalizzazione di mercato:
$31.45M
Reddito:
-
Utile/perdita netta:
$-563.30K
Rapporto P/E:
-0.3692
EPS:
-2.6
Flusso di cassa netto:
$-22.23M
1 W Prestazione:
-3.47%
1M Prestazione:
+1.05%
6M Prestazione:
-47.54%
1 anno Prestazione:
-26.91%
Intervallo 1D:
$0.95
$0.99
Intervallo di 1 settimana:
$0.91
$1.04
Portata 52W:
$0.91
$3.10
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Confronta PMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| PMN | 0.955 | 31.45M | 0 | -563.30K | -22.23M | -2.60 |
| VRTX | 449.54 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.83 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.38 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.78 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.25 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc (PMN) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of $0.31, Surp - GuruFocus.com
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
ProMIS Reports Positive Phase 1a Results for Alzheimer's Drug, Secures $30.3M Financing | PMN Stock News - StockTitan
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire
ProMIS Neurosciences (STU:23J0) PensionAndRetirementBenefit : €0.43 Mil (As of Jun. 2024) - GuruFocus.com
Biotech Shares Positive Phase I Data for Alzheimer's Treatment - Streetwise Reports
ProMIS Neurosciences Presents Positive Data from PMN310 - GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference - StockTitan
ProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
ProMIS Neurosciences stock hits 52-week low at $0.92 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now - Insider Monkey
ProMIS Neurosciences appoints new CEO Neil Warma By Investing.com - Investing.com Australia
ProMIS Neurosciences appoints new CEO Neil Warma - Investing.com
ProMIS Neurosciences Names Neil Warma Permanent CEO - TipRanks
ProMIS Neurosciences (NASDAQ:PMN) versus Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Analysis - Defense World
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN
Director Madge Shafmaster Acquires 200,000 Shares of ProMIS Neur - GuruFocus.com
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Acquires 60,000 Shares - Defense World
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $89,600.00 in Stock - Defense World
ProMIS Neurosciences director Shafmaster purchases $255,750 in stock By Investing.com - Investing.com South Africa
ProMIS Neurosciences director Shafmaster purchases $255,750 in stock - Investing.com India
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
BSE SME Popular Foundation slips on debut - Business Standard
Popular Foundations shares list at IPO price on BSE SME platform - The Economic Times
Popular Foundations makes tepid debut, shares list flat at ₹37 apiece on BSE SME platform - Upstox
How To Check Popular Foundations IPO Allotment Status - NDTV Profit
Taking a look at what insiders are doing to gauge the PureCycle Technologies Inc (PCT)’s direction - Knox Daily
Popular Foundations IPO allotment to be finalized today - IPO Watch
Prosperity Bancshares, Inc. (NYSE:PB) Shares Bought by Federated Hermes Inc. - Defense World
The Psychology of PureCycle Technologies Inc Inc. (PCT) Price Performance: Understanding Market Sentiment - The InvestChronicle
ProMIS Neurosciences to Showcase PMN310’s Ability to Target - GlobeNewswire
ProMIS unveils promising Alzheimer's antibody data at ICBN By Investing.com - Investing.com Australia
ProMIS unveils promising Alzheimer's antibody data at ICBN - Investing.com India
Pre-market Movers: TNON, FULC, SMFL, RYDE, NTGR… - RTTNews
ProMIS Neurosciences (NASDAQ:PMN) Trading Down 5% - Defense World
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):